References
Langdon K, Copeland L, Scheinberg A, Waugh MC, Burnett H, Wimalasundera N, et al. Comment on: “Botulinum toxin in the management of children with cerebral palsy”. Pediatr Drugs. 2019. https://doi.org/10.1007/s40272-019-00358-2.
Multani I, Manji J, Hastings-Ison T, Khot A, Graham K. Botulinum toxin in the management of children with cerebral palsy. Pediatr Drugs. 2019;21(4):261–81.
Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11(1):67–79.
Multani I, Manji J, Tang MJ, Herzog W, Howard JJ, Graham HK. Sarcopenia, cerebral palsy, and botulinum toxin type A. JBJS Rev. 2019;7(8):e4.
Hastings-Ison T, Sangeux M, Thomason P, Rawicki B, Fahey M, Graham HK. Onabotulinum toxin-A (Botox) for spastic equinus in cerebral palsy: a prospective kinematic study. J Child Orthop. 2018;12(4):390–7.
Paget SP, Swinney CM, Burton KLO, Bau K, O'Flaherty SJ. Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy. Dev Med Child Neurol. 2018;60(11):1172–7.
Montastruc J, Marque P, Moulis F, Bourg V, Lambert V, Durrieu G, et al. Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBase. Dev Med Child Neurol. 2017;59(3):329–34.
Rodda JM, Graham HK, Carson L, Galea MP, Wolfe R. Sagittal gait patterns in spastic diplegia. J Bone Joint Surg Br. 2004;86(2):251–8.
Valentine J, Davidson SA, Bear N, Blair E, Ward R, Thornton A, et al. Botulinum toxin and surgical intervention in children and adolescents with cerebral palsy: who, when and why do we treat? Disabil Rehabil. 2019. https://doi.org/10.1080/09638288.2019.1644381.
Novak I, McIntyre S, Morgan C, Campbell L, Dark L, Morton N, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013;55(10):885–910.
Hastings-Ison T, Graham K. Botulinum neurotoxin A, blinding, and bias. Dev Med Child Neurol. 2019. https://doi.org/10.1111/dmcn.14297.
Barber L, Hastings-Ison T, Baker R, Kerr Graham H, Barrett R, Lichtwark G. The effects of botulinum toxin injection frequency on calf muscle growth in young children with spastic cerebral palsy: a 12-month prospective study. J Child Orthop. 2013;7(5):425–33.
Schless SH, Cenni F, Bar-On L, Hanssen B, Kalkman B, O’Brien T, et al. Medial gastrocnemius volume and echo-intensity after botulinum neurotoxin A interventions in children with spastic cerebral palsy. Dev Med Child Neurol. 2019;61(7):783–90.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Kerr Graham received non-financial support from the National Health and Medical Research Council of Australia (NHMRC) Centre of Research Excellence in Cerebral Palsy (CRE-CP). None of the authors received financial support for the publication of this letter.
Conflict of interest
Iqbal Multani, Jamil Manji,Tandy Hastings-Ison, Abhay Khot, and Kerr Graham have no conflicts of interest that are directly relevant to the content of this letter.
Rights and permissions
About this article
Cite this article
Multani, I., Manji, J., Hastings-Ison, T. et al. Authors’ Reply to K. Langdon and Colleagues’ Comment on: “Botulinum Toxin in the Management of Children with Cerebral Palsy”. Pediatr Drugs 21, 497–499 (2019). https://doi.org/10.1007/s40272-019-00359-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40272-019-00359-1